123 related articles for article (PubMed ID: 21992803)
1. Affinity prediction on A3 adenosine receptor antagonists: the chemometric approach.
Luan F; Melo A; Borges F; Cordeiro MN
Bioorg Med Chem; 2011 Nov; 19(22):6853-9. PubMed ID: 21992803
[TBL] [Abstract][Full Text] [Related]
2. QSAR of adenosine receptor antagonists: Exploring physicochemical requirements for binding of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives with human adenosine A(3) receptor subtype.
Pran Kishore D; Balakumar C; Raghuram Rao A; Roy PP; Roy K
Bioorg Med Chem Lett; 2011 Jan; 21(2):818-23. PubMed ID: 21163647
[TBL] [Abstract][Full Text] [Related]
3. A3 adenosine receptor: homology modeling and 3D-QSAR studies.
Almerico AM; Tutone M; Pantano L; Lauria A
J Mol Graph Model; 2013 May; 42():60-72. PubMed ID: 23567933
[TBL] [Abstract][Full Text] [Related]
4. The identification of the 2-phenylphthalazin-1(2H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A3 adenosine receptor antagonists.
Poli D; Catarzi D; Colotta V; Varano F; Filacchioni G; Daniele S; Trincavelli L; Martini C; Paoletta S; Moro S
J Med Chem; 2011 Apr; 54(7):2102-13. PubMed ID: 21401121
[TBL] [Abstract][Full Text] [Related]
5. Topological sub-structural molecular design (TOPS-MODE): a useful tool to explore key fragments of human A3 adenosine receptor ligands.
Saíz-Urra L; Teijeira M; Rivero-Buceta V; Helguera AM; Celeiro M; Terán MC; Besada P; Borges F
Mol Divers; 2016 Feb; 20(1):55-76. PubMed ID: 26205409
[TBL] [Abstract][Full Text] [Related]
6. Recent advances on A₃ adenosine receptor antagonists by QSAR tools.
Luan F; Borges F; Cordeiro MN
Curr Top Med Chem; 2012; 12(8):878-94. PubMed ID: 22352915
[TBL] [Abstract][Full Text] [Related]
7. Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists.
Yaziji V; Rodríguez D; Gutiérrez-de-Terán H; Coelho A; Caamaño O; García-Mera X; Brea J; Loza MI; Cadavid MI; Sotelo E
J Med Chem; 2011 Jan; 54(2):457-71. PubMed ID: 21186795
[TBL] [Abstract][Full Text] [Related]
8. 2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation.
Squarcialupi L; Colotta V; Catarzi D; Varano F; Filacchioni G; Varani K; Corciulo C; Vincenzi F; Borea PA; Ghelardini C; Di Cesare Mannelli L; Ciancetta A; Moro S
J Med Chem; 2013 Mar; 56(6):2256-69. PubMed ID: 23427825
[TBL] [Abstract][Full Text] [Related]
9. Receptor-driven identification of novel human A₃ adenosine receptor antagonists as potential therapeutic agents.
Paoletta S; Federico S; Spalluto G; Moro S
Methods Enzymol; 2010; 485():225-44. PubMed ID: 21050920
[TBL] [Abstract][Full Text] [Related]
10. New 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives as potent and selective human A3 adenosine receptor antagonists.
Baraldi PG; Preti D; Zaid AN; Saponaro G; Tabrizi MA; Baraldi S; Romagnoli R; Moorman AR; Varani K; Cosconati S; Di Maro S; Marinelli L; Novellino E; Borea PA
J Med Chem; 2011 Jul; 54(14):5205-20. PubMed ID: 21675777
[TBL] [Abstract][Full Text] [Related]
11. QSAR modeling of the rodent carcinogenicity of nitrocompounds.
Helguera AM; Cordeiro MN; Pérez MA; Combes RD; González MP
Bioorg Med Chem; 2008 Mar; 16(6):3395-407. PubMed ID: 18295489
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore elucidation for a new series of 2-aryl-pyrazolo-triazolo-pyrimidines as potent human A3 adenosine receptor antagonists.
Cheong SL; Federico S; Venkatesan G; Paira P; Shao YM; Spalluto G; Yap CW; Pastorin G
Bioorg Med Chem Lett; 2011 May; 21(10):2898-905. PubMed ID: 21511471
[TBL] [Abstract][Full Text] [Related]
13. BCUT descriptors to predicting affinity toward A3 adenosine receptors.
González MP; Terán C; Teijeira M; Besada P; González-Moa MJ
Bioorg Med Chem Lett; 2005 Aug; 15(15):3491-5. PubMed ID: 15990306
[TBL] [Abstract][Full Text] [Related]
14. Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists: synthesis, biological evaluation, and development of an A1 bovine receptor model.
Tuccinardi T; Schenone S; Bondavalli F; Brullo C; Bruno O; Mosti L; Zizzari AT; Tintori C; Manetti F; Ciampi O; Trincavelli ML; Martini C; Martinelli A; Botta M
ChemMedChem; 2008 Jun; 3(6):898-913. PubMed ID: 18338422
[TBL] [Abstract][Full Text] [Related]
15. Affinity prediction on A1 adenosine receptor agonists: the chemometric approach.
Fossa P; Mosti L; Bondavalli F; Schenone S; Ranise A; Casolino C; Forina M
Bioorg Med Chem; 2006 Mar; 14(5):1348-63. PubMed ID: 16263293
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel A3 adenosine receptor ligands based on chromone scaffold.
Gaspar A; Reis J; Kachler S; Paoletta S; Uriarte E; Klotz KN; Moro S; Borges F
Biochem Pharmacol; 2012 Jul; 84(1):21-9. PubMed ID: 22433284
[TBL] [Abstract][Full Text] [Related]
17. Molecular modeling study on potent and selective adenosine A(3) receptor agonists.
Dal Ben D; Buccioni M; Lambertucci C; Marucci G; Thomas A; Volpini R; Cristalli G
Bioorg Med Chem; 2010 Nov; 18(22):7923-30. PubMed ID: 20943397
[TBL] [Abstract][Full Text] [Related]
18. Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
Pérez-Garrido A; Morales Helguera A; Abellán Guillén A; Cordeiro MN; Garrido Escudero A
Bioorg Med Chem; 2009 Jan; 17(2):896-904. PubMed ID: 19056282
[TBL] [Abstract][Full Text] [Related]
19. The application of a 3D-QSAR (autoMEP/PLS) approach as an efficient pharmacodynamic-driven filtering method for small-sized virtual library: application to a lead optimization of a human A3 adenosine receptor antagonist.
Moro S; Bacilieri M; Cacciari B; Bolcato C; Cusan C; Pastorin G; Klotz KN; Spalluto G
Bioorg Med Chem; 2006 Jul; 14(14):4923-32. PubMed ID: 16564691
[TBL] [Abstract][Full Text] [Related]
20. Exploring 3D-QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists+.
Bhattacharya P; Leonard JT; Roy K
J Mol Model; 2005 Nov; 11(6):516-24. PubMed ID: 15928917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
